Open Interest and Volume Dynamics
On 24 June 2026, Mankind Pharma’s open interest (OI) in derivatives rose from 25,851 contracts to 28,998 contracts, an absolute increase of 3,147 contracts or 12.17%. This expansion in OI was accompanied by a total volume of 39,473 contracts traded, indicating robust participation from traders and investors. The futures segment alone accounted for a value of approximately ₹58,979 lakhs, while options contributed a staggering ₹16,996.5 crores in notional value, culminating in a combined derivatives turnover of ₹60,326.27 lakhs.
The underlying stock price closed at ₹2,492, having touched an intraday low of ₹2,465.5, down 2.5% from the previous day’s close. Notably, the weighted average price of traded contracts skewed closer to the day’s low, suggesting that the bulk of trading activity occurred near the lower price levels. This price action, combined with rising OI, often points to fresh positions being initiated rather than existing ones being squared off.
Price Performance and Moving Averages
Despite the surge in derivatives activity, Mankind Pharma’s stock price underperformed its sector by 1.76% and the Sensex by 2.49% on the day. The stock has been on a two-day losing streak, falling a cumulative 1.96%. However, it remains comfortably above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling that the medium- to long-term trend remains intact. This divergence between short-term weakness and longer-term strength may be attracting speculative interest in the derivatives market.
Investor Participation and Liquidity
Investor participation has notably increased, with delivery volumes on 23 June rising by 139.31% to 6.08 lakh shares compared to the five-day average. This surge in delivery volume indicates genuine accumulation or distribution by investors rather than purely speculative trading. The stock’s liquidity is sufficient to support sizeable trades, with a 2% threshold of the five-day average traded value allowing for trade sizes up to ₹3.59 crore without significant market impact.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Market Positioning and Potential Directional Bets
The increase in open interest alongside rising volumes and a slight price decline suggests that market participants may be positioning for a directional move, possibly anticipating volatility or a correction. The fact that the weighted average price of futures traded was closer to the day’s low implies that new short positions could be building, or alternatively, that buyers are stepping in at lower levels to accumulate.
Given Mankind Pharma’s mojo score of 72.0 and an upgraded mojo grade from Hold to Buy as of 18 June 2026, there is a positive fundamental backdrop supporting the stock. The mid-cap pharmaceutical company, with a market capitalisation of ₹1,02,807.09 crore, operates in a sector that has shown resilience amid broader market fluctuations. This fundamental strength may be encouraging institutional investors to establish fresh positions in derivatives as a hedge or to leverage anticipated upside.
Comparative Sector and Index Performance
While Mankind Pharma’s stock declined by 1.55% on the day, the Pharmaceuticals & Biotechnology sector gained 0.18%, and the Sensex rose 0.94%. This relative underperformance could be a short-term correction or profit-taking phase. However, the sustained open interest growth and rising delivery volumes indicate that the underlying investor conviction remains firm, possibly reflecting expectations of a rebound or sustained growth in the medium term.
Technical Indicators and Trend Assessment
The stock’s position above all major moving averages suggests a bullish medium-term trend, despite recent short-term weakness. The rising open interest in derivatives often precedes significant price moves, as it reflects increased commitment from traders. The current pattern may indicate that market participants are preparing for a directional breakout, either to the upside or downside, depending on upcoming sectoral news, earnings, or macroeconomic developments.
Want to dive deeper on Mankind Pharma Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Implications for Investors
For investors, the surge in open interest and volume in Mankind Pharma’s derivatives market signals an opportune moment to closely monitor the stock’s price action and sector developments. The upgraded mojo grade to Buy and a solid mojo score of 72.0 reinforce the stock’s favourable outlook. However, the recent price softness and underperformance relative to the sector suggest caution in the short term.
Investors may consider using derivatives to hedge existing positions or to speculate on potential volatility. The stock’s liquidity and rising delivery volumes provide a conducive environment for both institutional and retail participants to execute sizeable trades without undue price impact.
Outlook and Conclusion
Mankind Pharma Ltd’s recent open interest surge in derivatives, combined with mixed price signals and strong fundamental ratings, paints a nuanced picture. While short-term price weakness has emerged, the underlying investor interest and technical positioning suggest that the stock remains well poised for a potential rebound or sustained growth phase. Market participants should watch for confirmation of directional moves through price and volume patterns in the coming sessions.
Overall, the data points to a market that is actively repositioning around Mankind Pharma, reflecting both caution and optimism amid evolving sector dynamics and company fundamentals.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
